Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Micafungin is a semisynthetic lipopeptide antifungal agent of the echinocandin class. It is used for the treatment and prevention of various Candida infections, including candidemia (fungal infection in the blood), acute disseminated candidiasis, esophageal candidiasis (infection of the throat), candida peritonitis and abscesses (infection in the abdomen), and as prophylaxis against Candida infections in patients undergoing hematopoietic stem cell transplantation. Micafungin acts by inhibiting beta‑1,3‑D‑glucan synthase—an enzyme essential for fungal cell wall synthesis—leading to disruption of fungal cell wall integrity and ultimately fungal death. It is fungicidal against some Candida species but generally fungistatic against Aspergillus species[1][2][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on micafungin.